Literature DB >> 12670296

Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment.

Georg Brabant1.   

Abstract

Acromegaly is caused by chronic excess secretion of growth hormone (GH) and resultant persistent elevation in concentrations of insulin-like growth factor-I (IGF-I), also called somatomedin-C. A number of diagnostic tests are available to support the diagnosis of acromegaly, but those that rely on measurement of serum GH concentrations have important limitations. Concentrations of serum IGF-I, which is produced principally in the liver and mediates the actions of GH, have been shown to correlate with clinical and metabolic markers of disease activity. Additionally, normalisation of IGF-I levels in acromegaly is associated with the resolution of symptoms and normal life expectancy. Thus, serum IGF-I is an important marker of disease activity and a sensitive, practical, and reliable measure of integrated GH concentrations in patients with acromegaly.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12670296     DOI: 10.1530/eje.0.148s015

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  11 in total

1.  Reference ranges for an automated chemiluminescent assay for serum insulin-like growth factor I (IGF-I) in a large population of healthy adults from Buenos Aires.

Authors:  M Guitelman; F Smithuis; N Garcia Basavilbaso; C Aranda; B Fabre; A Oneto
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

2.  Variation of the baseline characteristics and treatment parameters over time: an analysis of 15 years of growth hormone replacement in adults in the German KIMS database.

Authors:  I Kreitschmann-Andermahr; S Siegel; F Francis; M Buchfelder; H J Schneider; P H Kann; H Wallaschofski; M Koltowska-Häggström; G Brabant
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

3.  PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics.

Authors:  Dong Hee Na; Kang Choon Lee; Patrick P DeLuca
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

4.  Medical therapy of acromegaly.

Authors:  U Plöckinger
Journal:  Int J Endocrinol       Date:  2012-04-10       Impact factor: 3.257

Review 5.  Acromegaly: a challenging condition to diagnose.

Authors:  Salma AlDallal
Journal:  Int J Gen Med       Date:  2018-08-24

6.  Robotic Radiosurgery for Persistent Postoperative Acromegaly in Patients with Cavernous Sinus-Invading Pituitary Adenomas-A Multicenter Experience.

Authors:  Felix Ehret; Markus Kufeld; Christoph Fürweger; Alfred Haidenberger; Paul Windisch; Susanne Fichte; Ralph Lehrke; Carolin Senger; David Kaul; Daniel Rueß; Maximilian Ruge; Christian Schichor; Jörg-Christian Tonn; Günter Stalla; Alexander Muacevic
Journal:  Cancers (Basel)       Date:  2021-01-31       Impact factor: 6.639

Review 7.  Management of acromegaly in Latin America: expert panel recommendations.

Authors:  Ariel Barkan; Marcello D Bronstein; Oscar D Bruno; Alejandro Cob; Ana Laura Espinosa-de-los-Monteros; Monica R Gadelha; Gloria Garavito; Mirtha Guitelman; Ruth Mangupli; Moisés Mercado; Lesly Portocarrero; Michael Sheppard
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

Review 8.  Normal levels of serum IGF-I: determinants and validity of current reference ranges.

Authors:  G Brabant; H Wallaschofski
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

Review 9.  Advancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease Paradigms.

Authors:  Michael A Mooney; Elias D Simon; Andrew S Little
Journal:  Front Surg       Date:  2016-07-28

10.  Serum N-Terminal Type III Procollagen Propeptide: An Indicator of Growth Hormone Excess and Response to Treatment in Feline Hypersomatotropism.

Authors:  S V Keyte; P J Kenny; Y Forcada; D B Church; S J M Niessen
Journal:  J Vet Intern Med       Date:  2016-07-18       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.